Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Share News (APH)

Share Price Information for Alliance Pharma (APH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 33.50
Bid: 33.30
Ask: 33.50
Change: 0.20 (0.60%)
Spread: 0.20 (0.601%)
Open: 33.40
High: 33.60
Low: 32.50
Prev. Close: 33.30
APH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Applied Graphene launches strategic review

Wed, 23rd Nov 2022 11:14

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Europa Metals Ltd, up 42% at 3.98 pence, 12-month range 2.5p-5.3p. The lead, zinc and silver mine developer enters into an option agreement with Denarius Metals Corp, granting Denarius the right to acquire up to 80% of its wholly-owned Spanish subsidiary, Europa Metals Iberia. The subsidiary holds the Toral project in northwest Spain. Should shareholders approve the deal, Europa would secure an initial USD4.0 million for the Toral project, with a potential future cash payment of USD2.0 million. The first amount would give Denarius a 51% stake and the second an additional 29%. Europa Metals also conditionally raises GBP580,000 via subscription of 12.9 million new shares at issue price of 4.5p, a 61% premium to the closing price of 2.8p on Tuesday.

----------

Zanaga Iron Ore Co Ltd, up 23% at 4.1p, 12-month range 1.7p-5.2p. The part owner of the Zanaga iron ore project in the Republic of Congo reaches an agreement to buy Glencore Projects' controlling shareholding in the project. This would be enacted via the purchase of Glencore Projects' 50% plus one share interest in Jumelles - an entity which indirectly holds the benefit of the ZIO project's mining license - in exchange for the issue of 286.3 million new shares to Glencore Projects. This would represent a shareholding of 48% in ZIOC. "The acquisition is value accretive to shareholders and increases effective equity ownership of the project by existing shareholders, enhancing their look-through ownership of the project and securing control of the project without paying any premium for such interest," says Chair Clifford Elphick. Glencore Projects is a subsidiary of Swiss-based miner Glencore PLC.

----------

AIM - LOSERS

----------

Alliance Pharma PLC, down 30% at 42.46p, 12-month range 41.28p-122p. The distributor of consumer healthcare brands and prescription medicines says some larger orders in the fourth quarter of 2022 will not materialise. This is due to a slower-than-expected recovery in the business-to-business market, as well as a hit to sales from "a one-off destocking effect". It now expects annual revenue to be at least GBP170 million, with underlying pretax profit of at least GBP30 million. This is compared with 2021's revenue of GBP163.2 million and underlying pretax profit of GBP42.2 million. CEO Peter Butterfield will take time off from the business "for personal reasons", and return in January. Chief Financial Officer Andrew Franklin will assume his responsibilities in the meantime.

----------

Applied Graphene Materials PLC, down 39% at 3p, 12-month range 3p-28.5p. The graphene developer begins strategic review in light of its "funding position and...the unfavourable conditions in small-cap equity markets". The options pursued may include raising funds from a specialist debt provider or strategic investor, selling its trade and assets, or selling shares in its main operating subsidiary. It also decides to begin statutory redundancy consultations with its employees, to protect its financial position in case the review does not reach "a satisfactory conclusion".

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
9 Sep 2014 15:00

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
9 Sep 2014 05:27

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
8 Sep 2014 15:15

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
8 Sep 2014 05:43

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
5 Sep 2014 14:56

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
5 Sep 2014 05:23

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
4 Sep 2014 15:10

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
4 Sep 2014 05:23

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
3 Sep 2014 15:12

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
9 Jul 2014 07:37

UK MORNING BRIEFING: Deutsche Bank Raises Shell View, Cuts BP

Read more
9 Jul 2014 07:36

Alliance Pharma Says Flat Revenue Met Its Expectations

Read more
21 May 2014 09:59

Alliance Pharma Trading In Line With Expectations

LONDON (Alliance News) - Alliance Pharma PLC Wednesday said trading in the first four months of 2014 has been in line with expectations, following a robust trading performance in 2013. In a statement released ahead of its annual general meeting Wednesday the speciality pharmaceutical compan

Read more
21 May 2014 08:36

Wednesday broker round-up UPDATE

African Minerals: Citi reduces target price from 260p to 190p, while leaving its buy recommendation unchanged. Alliance Pharma: Numis lowers target price from 39p to 37p and maintains an add rating. APR Energy: JP Morgan shifts target price from 1082p to 1089p keeping its overweight rating. Astra

Read more
26 Mar 2014 16:09

Alliance Pharma's 2013 pre-tax profit rises

Alliance Pharma's annual pre-tax profit gained 11 per cent to 12m pounds, on the back of three acquisitions. The pharmaceutical company reported a 1.4% rise in revenue to £45.5m and a 6% increase in earnings per share to 3.82p. The company said growth was "underpinned by the continuing success o

Read more
26 Mar 2014 12:53

Alliance Pharma Lifts Its 2013 Dividend As Profit And Margins Rise

LONDON (Alliance News) - Alliance Pharma PLC raised its dividend as it saw pretax profit rise in 2013, benefiting from improved margins and growth in its Hydromol dermatology range. Alliance Pharma declared Wednesday a final dividend of 0.605 pence per share, bringing its total dividend for

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.